FIELD: biotechnologies.SUBSTANCE: invention relates to compounds of general formula I, having cytostatic or cytotoxic activity, its pharmaceutically acceptable salts, tautomers or stereoisomers, a pharmaceutical composition on their basis. Compounds may be used for treatment of cancerous diseases. In the general formula IY is selected from the group comprising -CHRay- and -CHRay-CRby-CRcy- each Ray, Rby and Rcy are independently selected from hydrogen and non-substitute C1-C12-alkyl each R1, R2, R3, R4 and R5 are independently selected from hydrogen and non-substitute C1-C12-alkyl R6 is selected from NR8R9 and OR10 A means , W means NR7 R7 means hydrogen R8 means hydrogen R10 means non-substitute C2-C12-alkenyl each dotted line means unnecessary additional link, but when there is a triple link between atoms of carbon, to which R1 and R2 are attached, then R1 and R2 are absent, and when there is a triple link between carbon atoms, to which R3 and R4 are attached, then R3 and R4 are absent R9 is selected from substitute C2-C12-alkenyl and substitute C4-C2-alkenylyl, where substitutes are selected from the group, consisting of: halogen, OR, OCONHR and OH, protected with a simple silyl ether where R means hydrogen provided that whenever Y means -CHRay-CRby=CRcy- and there is a single or double link between atoms of carbon, to which R3 and R4 are attached, then R9 means substitute C4-C12-alkenylyl and each R16, R17 and R18 are independently selected from hydrogen and ORa each Ra is selected from hydrogen or non-substitute C1-C12-alkyl.EFFECT: higher efficiency of compound application.Изобретение относится к соединениям общей формулы I, обладающим цитостатической или цитотоксической активностью, его фармацевтически приемлемым солям, таутомерам или стереоизомерам, фармацевтической композиции на их основе, их применению, способам получения и способам лечения с их использованием. Соединения могут быть использованы для лечения раковых заболеваний. В общей формуле IY выбирают
